Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928447 · ClinicalTrials.gov registry record · Phase 2
Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis
A Phase 2 study of Dermatitis, Allergic Contact, sponsored by Halozyme Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT00928447 is a Phase 2 study of Dermatitis, Allergic Contact that has completed, run by Halozyme Therapeutics. The registered enrollment target is 22 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00928447, a Phase 2 study of Dermatitis, Allergic Contact, has completed, sponsored by Halozyme Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the effect and safety of rHuPH20 or placebo for the prevention and treatment of skin allergic reaction to nickel. The study drug and placebo will be administered by intradermal injection.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG rHuPH20
Study Locations (1)
Indiana
- Symbio Phase I Unit, Saint Anthony Memorial Research Center - Michigan City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2009-06-23 |
| Est. Completion | 2009-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00928447
The ClinicalTrials.gov registry entry for NCT00928447 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Halozyme Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermatitis, Allergic Contact appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00928447 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT00928447 about?
NCT00928447 is a clinical study titled "Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis". The purpose of this study is to compare the effect and safety of rHuPH20 or placebo for the prevention and treatment of skin allergic reaction to nickel. The study drug and placebo will be administered by intradermal injection.
What is the current status of trial NCT00928447?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2009-06-23. Estimated completion is 2009-09-13.
What conditions does trial NCT00928447 study?
This clinical trial studies the following conditions: Dermatitis, Allergic Contact.
What interventions are being tested in trial NCT00928447?
The interventions under investigation include: Placebo (DRUG), rHuPH20 (DRUG).
Who is sponsoring clinical trial NCT00928447?
This trial is sponsored by Halozyme Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00928447 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.